Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Randomized Trial of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas

NCT05809830 is registered in ClinicalTrials.gov with Grupo Espanol de Investigacion en Sarcomas as lead sponsor.

NCT NCT05809830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05809830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Randomized Trial of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas
Lead sponsor
Grupo Espanol de Investigacion en Sarcomas
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 29, 2023
Completion date
May 8, 2026
Enrollment
152 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced soft-tissue sarcoma